Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02231996
NCT02231996UnknownNot Applicable

Chronic Granulomatous Disease Study in China

Shanghai Children's Medical Center1 site in 1 country50 target enrollmentStarted: September 2014Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
50
Locations
1
Primary Endpoint
times of pneumonia
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

CGD is a rare inherited primary immunodeficiency which is caused by the defect in one of the subunits of NADPH oxidase complex.We tend to collect and analyze Chinese CGD patients who are diagnosed in hospitals affiliated to Shanghai Jiao Tong University School of Medicine, including clinical feature, laboratory data and genetic information. we aim to find out clinical, distribution, genetic characteristic of CGD in Chinese population, etc., thus further improving the level of diagnosis and treatment for CGD.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
1 Day to 18 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •x-linked and AR-linked Chronic Granulomatous Disease
  • •history of life-threatening severe infections
  • •A functional assay demonstrating abnormal NADPH oxidase function or clinical history consistent with CGD

Exclusion Criteria

  • •Presence of other primary immunodeficiency syndromes that do not meet the clinical and laboratory criteria for CGD.

Outcomes

Primary Outcomes

times of pneumonia

Time Frame: 2 years

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Shanghai Children's Medical Center
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 1
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous DiseaseGranulomatous Disease, Chronic, X-linked
NCT02234934University of California, Los Angeles10
Recruiting
Phase 1
Lentiviral Gene Therapy for p47 AR-CGDP47-Phox, Deficiency of
NCT05207657Great Ormond Street Hospital for Children NHS Foundation Trust5
Withdrawn
Phase 1
Lentiviral Gene Therapy for X-Linked Chronic Granulomatous Disease (X-CGD)Granulomatous Disease, Chronic, X-linked, Variant
NCT01381003Great Ormond Street Hospital for Children NHS Foundation Trust
Enrolling By Invitation
Phase 1
pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)p47Autosomal RecessiveChronic Granulomatous Disease
NCT06253507National Institute of Allergy and Infectious Diseases (NIAID)10
Unknown
Not Applicable
Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995Granulomatous Disease, Chronic
NCT02082353National Institute of Allergy and Infectious Diseases (NIAID)1,480